CCIA
TBPH

Campbell & Co Investment Adviser’s Theravance Biopharma TBPH Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,839
Closed -$419K – 1352
2026
Q1 		$419K Sell
25,839
-10,660
-29% -$189K 0.02% 798
2025
Q4 		$683K Sell
36,499
-16,118
-31% -$267K 0.03% 712
2025
Q3 		$768K Buy
52,617
+2,225
+4% +$28.1K 0.06% 531
2025
Q2 		$556K Buy
+50,392
New +$490K 0.04% 749
2024
Q3 		– Sell
-44,180
Closed -$375K – 1322
2024
Q2 		$375K Buy
44,180
+28,678
+185% +$259K 0.03% 756
2024
Q1 		$139K Buy
+15,502
New +$144K 0.01% 1045
2022
Q2 		– Sell
-25,100
Closed -$240K – 911
2022
Q1 		$240K Buy
+25,100
New +$246K 0.06% 562
2021
Q4 		– Sell
-27,200
Closed -$201K – 815
2021
Q3 		$201K Buy
+27,200
New +$304K 0.07% 523
2020
Q1 		– Sell
-8,928
Closed -$231K – 469
2019
Q4 		$231K Buy
+8,928
New +$174K 0.07% 527

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Campbell & Co Investment Adviser's TBPH Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 25,839 shares — an estimated $419K sold.

Campbell & Co Investment Adviser first reported a position in TBPH in Q4 2019 and held it in 9 quarters. The position peaked at $768K in Q3 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 25,839 Theravance Biopharma shares in Q2 2026, an estimated $419K.
  • Campbell & Co Investment Adviser first reported a position in Theravance Biopharma in Q4 2019 and held it in 9 quarters.
  • Campbell & Co Investment Adviser's Theravance Biopharma position peaked at $768K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.